Pancreatitis por hipertrigliceridemia asociada a anticonceptivos orales: Reporte de un caso
PDF (Español (España))
HTML (Español (España))



How to Cite

Altamar, H., & Stephens, I. (2017). Pancreatitis por hipertrigliceridemia asociada a anticonceptivos orales: Reporte de un caso. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 4(1), 40–42.


La hipertrigliceridemia es una de las causas de pancreatitis aguda, generalmente con un riesgo mayor cuando su valor supera los 1.000 mg/dl. Se han descrito diferentes alternativas terapéuticas para el tratamiento de pacientes con pancreatitis por hipertrigliceridemia, entre ellas la infusión de insulina. Se reporta el caso de un paciente con hipertrigliceridemia muy severa que presentó pancreatitis aguda y su evolución fue favorable con la terapia con insulina.
PDF (Español (España))
HTML (Español (España))


1. Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol. 2009;104(4):984-91.
2. Tenner S. Drug-induced acute pancreatitis: underdiagnosis and overdiagnosis. Dig Dis Sci. 2010;55(10):2706-8.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection Ea, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among us adults: Findings from the third national health and nutrition examination survey. JAMA. 2002;287(3):356-9.
5. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97(9):2969-89.
6. Scherer J, Singh VP, Pitchumoni CS, Yadav D. Issues in hypertriglyceridemic pancreatitis: an update. J Clin Gastroenterol. 2014;48(3):195-203.
7. Fortson MR, Freedman SN, Webster PD. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134-9.
8. Lloret Linares C, Pelletier AL, Czernichow S, Vergnaud AC, Bonnefont-Rousselot D, Levy P, et al. Acute pancreatitis in a cohort of 129 patients referred for severe hypertriglyceridemia. Pancreas. 2008;37(1):13-2.
9. Khan AS, Latif SU, Eloubeidi MA. Controversies in the etiologies of acute pancreatitis. JOP. 2010;11(6):545-52.
10. Brucker C, Hedon B, The HS, Höschen K, Binder N, Christoph A. Long-term efficacy and safety of a monophasic combined oral contraceptive containing 0.02 mg ethinylestradiol and 2 mg chlormadinone acetate administered in a 24/4-day regimen. Contraception. 2010;81(6):501-9.
11. Haber PS, Wilson JS, Apte MV, Hall W, Goumas K, Pirola RC. Lipid intolerance does not account for susceptibility to alcoholic and gallstone pancreatitis. Gastroenterology. 1994;106(3):742-8.
12. Goyal H, Smith B, Bayer C, Rutherford C, Shelnut D. Differences in Severity and Outcomes Between Hypertriglyceridemia and Alcohol-Induced Pancreatitis. N Am J Med Sci. 2016;8(2):82-7.
13. Arbel Y, Weinstein D, Yogev R, Halevy A. Acute pancreatitis following clomiphene citrate treatment: case report and review of the literature. Int J Surg. 2008;6(6):483-4.
14. Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. Pharmacotherapy. 2005;25(10):1348-52.
15. Winkler UH, Röhm P, Höschen K. An open-label, comparative study of the effects of a dose-reduced oral contraceptive containing 0.02 mg ethinylestradiol/2 mg chlormadinone acetate on hemostatic parameters and lipid and carbohydrate metabolism variables. Contraception. 2010;81(5):391-400.
16. Toskes PP. Hyperlipidemic pancreatitis. Gastroenterol Clin North Am. 1990;19(4):783-91.
17. Yang F, Wang Y, Sternfeld L, Rodriguez JA, Ross C, Hayden MR, et al. The role of free fatty acids, pancreatic lipase and Ca+ signalling in injury of isolated acinar cells and pancreatitis model in lipoprotein lipase-deficient mice. Acta Physiol (Oxf ). 2009;195(1):13-28.
18. Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al. Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher. 2010;25(3):83- 177.
19. Stefanutti C, Di Giacomo S, Labbadia G. Timing clinical events in the treatment of pancreatitis and hypertriglyceridemia with therapeutic plasmapheresis. Transfus Apher Sci. 2011;45(1):3-7.
20. Stefanutti C, Julius U. Treatment of primary hypertriglyceridemia states- -General approach and the role of extracorporeal methods. Atheroscler Suppl. 2015;18:85-94.
21. Mikhail N, Trivedi K, Page C, Wali S, Cope D. Treatment of severe hypertriglyceridemia in nondiabetic patients with insulin. Am J Emerg Med. 2005;23(3):415-7.
22. Näsström B, Olivecrona G, Olivecrona T, Stegmayr BG. Lipoprotein lipase during continuous heparin infusion: tissue stores become partially depleted. J Lab Clin Med. 2001;138(3):206-13.
23. Jain P, Rai RR, Udawat H, Nijhawan S, Mathur A. Insulin and heparin in treatment of hypertriglyceridemia-induced pancreatitis. World J Gastroenterol. 2007;13(18):2642-3.
24. Ballantyne CM, Grundy SM, Oberman A, Kreisberg RA, Havel RJ, Frost PH, et al. Hyperlipidemia: diagnostic and therapeutic perspectives. J Clin Endocrinol Metab. 2000;85(6):2089-112.
25. Rosenson RS. Current overview of statin-induced myopathy. Am J Med. 2004;116(6):408-16.

Authors must state that they reviewed, validated and approved the manuscript's publication.  Moreover, they must sign a model release that should be sent.  A copy may be reviewed here




Download data is not yet available.